In vitro and in vivo anti-melanoma effects of ciglitazone.

@article{Botton2009InVA,
  title={In vitro and in vivo anti-melanoma effects of ciglitazone.},
  author={Thomas Botton and Alexandre Puissant and Philippe Bahadoran and Jean S{\'e}bastien Annicotte and Lluis Fajas and Ortonne Jp and Genevieve Gozzerino and Thamilla Zamoum and Sophie Tartare-Deckert and Corine Bertolotto and Robert Ballotti and St{\'e}phane Rocchi},
  journal={The Journal of investigative dermatology},
  year={2009},
  volume={129 5},
  pages={
          1208-18
        }
}
Activation of PPARgamma by synthetic ligands, thiazolidinediones, inhibits the proliferation of cancer cells. In this report, focusing our attention on ciglitazone, we show that ciglitazone inhibits melanoma growth by inducing apoptosis and cell-cycle arrest, whereas normal melanocytes are resistant to ciglitazone. In melanoma cells, ciglitazone-induced apoptosis is associated with caspase activations and a loss of mitochondrial membrane potential. Induction of cell-cycle arrest by ciglitazone… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics

Jelena Grahovac, Tatjana Srdić-Rajić, +3 authors Siniša Radulović
  • Cancer biology & medicine
  • 2019

Editor's Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis.

  • Toxicological sciences : an official journal of the Society of Toxicology
  • 2017
VIEW 2 EXCERPTS
CITES RESULTS

References

Publications referenced by this paper.
SHOWING 1-10 OF 48 REFERENCES

Epidemiology and prevention of cutaneous melanoma

  • Current treatment options in oncology
  • 2006
VIEW 1 EXCERPT